NCT01226693 - A Study In Healthy Volunteers To Assess The Safety, Tolerability, And Relative Oral Bioavailability Of Three Formulations Of PH-797804 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions

Healthy

Interventions

DRUG

PH-797804 material sparing tablet

oral, 6mg, single dose

DRUG

PH-797804 Phase2b/3 with sodium lauryl sulphate

oral, 6mg, single dose

DRUG

PH-797804 Phase2b/3 with sodium lauryl sulphate

oral, 6mg, single dose

DRUG

PH-797804 material sparing tablet

oral, 6mg, single dose

DRUG

PH-797804 material sparing tablet

oral, 6mg, single dose

DRUG

PH-797804 Phase2b/3 without sodium lauryl sulphate

oral, 6mg, single dose

DRUG

PH-797804 Phase2b/3 without sodium lauryl sulphate

oral, 6mg, single dose

DRUG

PH-797804 material sparing tablet

oral, 6mg, single dose

DRUG

PH-797804 Phase2b/3 without sodium lauryl sulphate

oral, 6mg, single dose

DRUG

PH-797804 Phase2b/3 with sodium lauryl sulphate

oral, 6mg, single dose

DRUG

PH-797804 Phase2b/3 with sodium lauryl sulphate

oral, 6mg, single dose

DRUG

PH-797804 Phase2b/3 without sodium lauryl sulphate

oral, 6mg, single dose

Trial Locations (1)

188770

Pfizer Investigational Site, Singapore